Due to harboring BCR::ABL1 translocation, the inhibitory activity of imatinib over SUP-B15 is not a surprise and has already been described in the literature [33]; however, the inhibitory concentration achieved with AZD2461 of 344.3 nM in 72 h, close to the 329.2 nM of the inhibition of imatinib, suggests that the use of PARPis may be as effective as the treatment with TKI in models of ALL p190+. This evidence concerns the gene BCR and acute lymphoblastic leukemia.